CD101 and prostate carcinoma: In addition, targeting the Malat1 and AR-v7 axis using Malat1-short interfering RNAs (siRNAs) in enzalutamide-resistant prostate cancer cell lines and mouse models suppressed enzalutamide-resistant prostate cancer progression [113].